Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Severity and QOL scores during sirolimus treatment

From: The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies

  Severity score QOL score
All score Physical score Psychological score
Pretreatment 6 months p valuea Pretreatment 6 months p valuea Pretreatment 6 months p valuea Pretreatment 6 months p valuea
All patients (n = 20) 8.0 (3–20) 5.0 (1–20) 0.0029 58.1 (17.4–94.6) 77.3 (7.7–91.3) 0.0129 50.0 (0–100) 77.6 (0–100) 0.0105 65.0 (12.5–100) 75.8(16.7–100) 0.0052
PR patients (n = 10) 8.0 (3–13) 4.5 (1–7) 0.0020 58.1 (17.4–84.7) 76.2 (51.1–91.3) 0.0117 48.4 (18.8–98.4) 77.6 (21.9–98.4) 0.0078 65.0 (12.5–78.1) 75.8 (60–90.5) 0.0156
SD patients (n = 10) 6.5 (3–20) 5.5 (1–20) 0.4375 63.3 (23.9–94.6) 79.8 (7.7–91.3) 0.3828 53.1 (0–100) 69.5 (0–100) 0.367 67.5 (27.5–-100) 82.5 (16.7–100) 0.2188
  1. Values presented as median (range)
  2. PR partial response, SD stable disease
  3. aWilcoxon signed rank test for comparison between pretreatment and 6 months